Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 288 participants.

Also called NCT06669169

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 288 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06669169
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06669169. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-31 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
Condition
Heart Failure
Intervention (Drug)
Jia Shen Tablet Placebo
Intervention (Drug)
Low dose Jia Shen Tablet
Intervention (Drug)
High dose Jia Shen Tablet
Lead sponsor
Tasly Pharmaceutical Group Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct06669169
Content hash
78ca290801ce01a0678e8fce1c20132777f5d6da8ec01f3cba44ce3da5952d9a